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Abstract
Background: The multi-drug resistance transporter ABCG2, a member of the ATP-binding cassette (ABC)
transporter family, mediates the efflux of different immunotherapeutics used in multiple sclerosis (MS), e.g.,
teriflunomide (teri), cladribine, and mitoxantrone, across cell membranes and organelles. Hence, the modulation of
ABCG2 activity could have potential therapeutic implications in MS. In this study, we aimed at investigating the
functional impact of abcg2 modulation on teri-induced effects in vitro and in vivo.
Methods: T cells from C57BL/6 J wild-type (wt) and abcg2-knockout (KO) mice were treated with teri at different
concentrations with/without specific abcg2-inhibitors (Ko143; Fumitremorgin C) and analyzed for intracellular teri
concentration (HPLC; LS-MS/MS), T cell apoptosis (annexin V/PI), and proliferation (CSFE). Experimental autoimmune
encephalomyelitis (EAE) was induced in C57BL/6J by active immunization with MOG35–55/CFA. Teri (10 mg/kg body
weight) was given orally once daily after individual disease onset. abcg2-mRNA expression (spinal cord, splenic T
cells) was analyzed using qRT-PCR.
Results: In vitro, intracellular teri concentration in T cells was 2.5-fold higher in abcg2-KO mice than in wt mice.
Teri-induced inhibition of T cell proliferation was two fold increased in abcg2-KO cells compared to wt cells. T cell
apoptosis demonstrated analogous results with 3.1-fold increased apoptosis after pharmacological abcg2-inhibition
in wt cells. abcg2-mRNA was differentially regulated during different phases of EAE within the central nervous
system and peripheral organs. In vivo, at a dosage not efficacious in wt animals, teri treatment ameliorated clinical
EAE in abcg2-KO mice which was accompanied by higher spinal cord tissue concentrations of teri.
Conclusion: Functional relevance of abcg2 modulation on teri effects in vitro and in vivo warrants further
investigation as a potential determinant of interindividual treatment response in MS, with potential implications for
other immunotherapies.
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Introduction
The ATP-binding cassette (ABC) transporter family is
comprised of molecular transporters that use the energy
of ATP hydrolysis to translocate various molecules
across extra- and intracellular membranes in essential
physiological processes, e.g., nutrient uptake, osmotic
homeostasis, and protection from xenotoxins [1]. The
transporter ABCG2 is highly expressed at physiological
barriers like the intestinal epithelium, the blood-brain
barrier (BBB), and hepatocytes. It binds a variety of
approved pharmaceutical agents, contributing to their
pharmacodynamics and kinetics [2, 3].
Different immunotherapeutics used for the treatment
of multiple sclerosis (MS), i.e., teriflunomide (teri),
mitoxantrone, and cladribine, are known substrates of
ABCG2 [4–7]. Despite increasing treatment options in
MS, unmet needs include potential predictors of thera-
peutic response and adverse drug reactions to possibly
guide individualizing treatment strategies [8, 9].
Teri is an oral compound with presumed pleiotropic
mechanisms of action. One prominent target appears to
be selective inhibition of dihydro-orotate dehydrogenase
(DHODH), a key mitochondrial enzyme in the de novo
pyrimidine synthesis pathway, leading to a reduction in
proliferation of activated T and B lymphocytes [10, 11].
Here, we investigated whether modulation of abcg2 influ-
ences teri-induced effects in vitro in T cells and in vivo in
experimental autoimmune encephalomyelitis (EAE).
Materials and methods
Ethics approval, animal studies, and human samples
Animal experiments were approved by the local authorities
(Veterinary Office of the Canton of Bern, Switzerland, no.
BE 64/16; North Rhine-Westphalia authorities for animal
experimentation, no. 84-02.04.2015.A006). Wild-type (wt)
C57BL/6 J (Janvier, France) and abcg2 knockout (abcg2-
KO; St. Jude Children’s Research Hospital,Memphis, TN
[5];) mice (backcrossed to C57Bl/6 wt mice for > 10 gener-
ations) were used for in vivo (i.e., EAE) and in vitro studies.
Mice were kept under standardized, pathogen-free condi-
tions. Genotyping was performed with the KAPA Mouse
Genotyping Kit (KAPA Biosystems, Woburg, USA); pri-
mer: abcg2-KO1 5′-AGG CGA CCT CTT CCA AGA CT-
3′, abcg2-KO2 5′-GCA GCG CAT CGC CTT CTA TC-
3′, WT1 5′-GTG CCA CCA TGT TCA ACT TA-3′,
WT2 5′CTG CCA GAG TAG TGG AAG ATT-3′
(Microsynth, Balgach, Switzerland). Human studies were
approved by the local cantonal ethic committee Bern
(KEK-BE 2017-00060), and CD3+ T cells were isolated
from PBMCs of healthy donors.
Induction, teri treatment, and histopathology of EAE
Chronic EAE was induced by active immunization
with 100 μg myelin-oligodendrocyte-glycoprotein peptide
35–55 (MOG35–55) (Charité Berlin, Germany) in complete
Freund’s adjuvants (CFA) and disease severity was
assessed clinically using a 10-point EAE scale: 0, normal;
1, reduced tone of tail; 2, limp tail, impaired righting; 3,
absent righting; 4, gait ataxia; 5, mild paraparesis of hind
limbs; 6, moderate paraparesis; 7, severe paraparesis or
paraplegia; 8, tetraparesis; 9, moribund; 10, death [12].
Teri (provided by Sanofi Genzyme, Cambridge, USA) was
dissolved in 25mM Tris buffer (80 %) in H2O (20%) at a
pH of 7.5. After individual disease onset (score > 1), mice
were treated with teri (10mg/kg once daily, oral gavage
[13, 14];) or respective vehicle for 17–20 consecutive days.
Spinal cord tissue was embedded in paraffin and stained
with hematoxylin and eosin (H&E) or luxol fast blue
(LFB). Immunohistochemistry was performed for CD3+ T
cells (rat-α-human CD3, 1:100, AbD Serotec, Düsseldorf,
Germany), Mac3+ macrophages (rat-α-mouse Mac3, 1:
100; BD Pharmingen, Heidelberg, Germany), and B220/
CD45R+ B cells (rat-α-mouse CD45R, 1:200, AbD Sero-
tec). Images were captured with a slide scanner (Pannora-
mic 250 Flash III, 3DHISTECH, Budapest, Hungary), and
the inflammatory score (0, no inflammation; 1, cellular in-
filtration only in the perivascular areas and meninges; 2,
mild cellular infiltration; 3, moderate cellular infiltration
[15] or the demyelinated area (ratio of demyelinated area/
total area) or number of immune cells within lesions
was determined using CaseViewer (3DHISTECH). All
in vivo experiments and histological analyses were
performed in a blinded setup for the treatment group
and genotype of animals.
FACS analysis of splenic and inguinal lymph node
lymphocytes
Lymphocytes from PBS perfused mice suffering from
EAE (at day 4 ± 1 after initiation of therapy) or healthy
mice were isolated using a Wheaten homogenizer. Sub-
sequently, cells were filtered through a 100-μm nylon
mesh and washed (HBSS supplemented with 25mM
HEPES and 5% calf serum), and erythrocytes in splenic
samples were lysed. For in vitro teri treatment of spleno-
cytes from healthy mice, cells were incubated with
100 μM teri/DMSO or respective vehicle for 2 h at 37 °C
in 5mL medium (RPMI (Gibco) supplemented with 10%
FBS, 2% L-glutamine (Gibco), 1% NEAA (Gibco), 1% so-
dium pyruvate (Gibco), 1% PenStrep (Gibco), and 0.05
mM β-mercaptoethanol (Merck)). In vitro-treated cells
or cells from in vivo-treated mice were stimulated with
50 ng/mL phorbol myristate acetate (PMA; Alexix Bio-
chemicals), 1 mg/mL ionomycin (BioVision, Inc.), and
3.3 μl/5 mL GolgiStop (BD Biosciences) for 4 h at 37 °C
in 5 mL medium. After stimulation, cells were collected
and stained for CD4, CD25, and FoxP3 using the Treg
Detection Kit according to manufacturer’s protocol
(Myltenyi) or for intracellular cytokines (IFN-γ, IL-17,
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GM-CSF, IL-4, IL-10) and surface markers (CD45, CD4,
CD8) as adapted from [16]. For surface staining, cells
were incubated with primary antibody (Additional file 6:
Table S1) mixes in FACS buffer (DPBS, 2.5% FBS, and
0.1% NaN3) for 30 min on ice. After a washing step, cells
were fixed and permeabilized for 20 min on ice (BD Bio-
sciences; Cytofix/CytopermTM). Cells were washed and
incubated for intracellular staining with primary antibody
(Additional file 6: Table S1) mixes in Perm/WashTM solu-
tion (BD Biosciences) for 30min on ice. Cells were washed
twice after the staining and resuspended in FACS buffer.
Flow cytometry was performed using an Attune NxT flow
cytometer (Thermofisher scientific). Data analysis was
performed with FlowJo software.
Isolation of murine and human T cells and flow cytometry
analyses
Isolation of splenic T cells of healthy mice was performed
using the Pan T Cell Isolation Kit II according to the man-
ufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach,
Germany). Activated T cells (anti-murine-CD3, 10 μg/mL
+ anti-murine-CD28, 10 ng/mL; 5% CO2, 37 °C [17];) were
treated with teri (12.5–100 μM/DMSO, final concentra-
tion 0.1%) or DMSO (final concentration 0.1%) as control
[18]. After 48 h of incubation, cell proliferation was quan-
tified using the CellTraceTM CFSE (carboxy-flourescein-
diacetat-succinimidylester) Cell Proliferation Kit according
to the manufacturer’s protocol (Invitrogen, Karlsruhe,
Germany; flow cytometry) (Additional file 5: Figure S5A).
For pharmacological abcg2 inhibition in wt cells, Fumitre-
morgin C (FTC, 10 μM) or Ko143 (10 μM) were used.
After 48 h of incubation, T cells were analyzed for apop-
tosis using the FITC annexin V (Anx) Apoptosis Detec-
tion Kit I according to manufacturer’s protocol (BD
Biosciences, Heidelberg, Germany; flow cytometry) (Add-
itional file 5: Figure S5B). Human T cells (Pan T Cell Iso-
lation Kit (human), Miltenyi Biotec) were stimulated (anti-
CD3e, 1 μg/mL, Invitrogen, Karlsruhe, Germany) and
treated with teri (50 or 100 μM) with or without FTC
(10 μM), and T cells were analyzed for apoptosis after 72 h
as described above (Additional file 5: Figure S5B).
Measurement of teri concentration by HPLC and LC-MS/MS
For teri plasma and tissue concentration, blood and respect-
ive organs were collected from PBS-perfused animals after
teri-treatment (MOG35–55-immunized or non-immunized,
17–20 days after initiation of therapy). Blood was collected
by cardiac puncture and plasma was stored at − 80 °C. For
teri tissue concentration, the liver, spleen, brain, and spinal
cord were frozen in liquid nitrogen and stored at − 80 °C.
For intracellular concentrations after in vitro teri treatment,
collected cells were diluted in acetonitrile (Bisolve, Valkens-
waard, Netherlands) and subsequently lysed using ultra-
sound. High-performance liquid chromatography (HPLC)
followed by liquid chromatography-mass spectrometry (LC-
MS/MS) was performed as described previously [19].
Quantitative real-time PCR analyses
For quantitative real-time PCR (qRT-PCR), healthy animals
(Ctrl.) or animals during the acute (16 or 18 days after
immunization) or chronic (26 days after immunization)
phase were perfused with PBS. The spleen, isolated T cells
from the spleen diluted in RLT buffer (Qiagen, Germany),
spinal cord tissue, and liver were frozen in liquid nitrogen
and stored at − 80 °C. Microvessels from the spinal cord
and brain were isolated as previously described [20]. RNA
was isolated using TRIZOL followed by the RNAeasy Kit
Mini (Qiagen, Germany) and transcribed to cDNA accord-
ing to the manufacturer’s protocol (Super Mix; Quanta Bio-
sciences, USA). QRT-PCR was performed on an ABI real-
time PCR system (Applied Biosystems, Darmstadt,
Germany) using PerfeCTa FastMixII master mix (Quanta
Bioscience) and abcg2-primer (5′→3′ sense-GCA CCT
CAA CCT GCC CAT T; antisense-TCA GGG TGC CCA
TCA CAA C; FAM-CAT CTT GAA CCA CAT AAC
CTG AAC AGC ATT TG; Microsynth, Baldgach,
Switzerland), normalized to the housekeeping gene β-actin
(primer: Mm00607939_s1 Actb, Applied Biosystems) using
the ΔΔct method.
Statistical methods
Statistical analyses were performed using GraphPad
Prism 7 (GraphPad Software Inc., San Diego, USA). Data
is presented as mean ± standard error of the mean
(SEM). Statistical tests performed are indicated in the
figure legends. Probability level (p value) is indicated as
*p < 0.05, **p < 0.01, and ***p < 0.001.
Results
abcg2-deficiency or pharmacological inhibition increases
teriflunomide effects in splenic T cells
We first investigated whether abcg2 activity determines
intracellular teri concentrations. Intracellular teri con-
centration in splenic T cells from abcg2-KO mice was
2.5-fold higher than in T cells from wt animals (p <
0.05; Fig. 1a).
To further investigate whether reduced abcg2 activity
and increased intracellular teri concentration are associ-
ated with functional effects, we analyzed teri-induced in-
hibition of proliferation as well as apoptosis in splenic
CD3+ T cells. Increased teri-induced inhibition of T cell
proliferation was observed in cells from abcg2-KO mice
(12.5–100 μM teri, p < 0.05; Fig. 1b). Likewise, pharmaco-
logical abcg2 inhibition in T cells from wt mice led to an
increase of teri-induced apoptosis (Ko143 vs. DMSO: 3.1-
fold, p < 0.05; FTC vs. DMSO: 2.8-fold, p > 0.05; Fig. 1c).
In contrast, apoptosis was not increased in human T cells
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after ABCG2 inhibition (Δ apoptosis, DMSO = 4.8 %;
FTC = 5.9%; Wilcoxon test, p > 0.05; n = 5).
We further evaluated potential immunomodulatory
effects of teri on T cell responses in vitro. However,
neither in the percentage fractions of CD4+CD45+ and
CD8+CD45+ T cells nor in the cytokine production
(IFN-γ, IL-17, GM-CSF, IL-2, IL-10) relevant differences
between genotypes were observed. Only secretion of IL-
17 was increased in abcg2-KO cells compared to wt
cells, however, without differences compared to respect-
ive teri-treated cells (Additional file 1: Figure S1).
abcg2-deficency increases the therapeutic response to
teriflunomide in experimental autoimmune
encephalomyelitis
Next, we investigated whether abcg2-mRNA expression is
regulated during different phases of EAE in wt mice. Within
the spinal cord, abcg2-mRNA expression levels decreased
during the acute phase (d16 or d18 after immunization; Ctrl.
vs. acute: fivefold, p > 0.05; Additional file 2: Figure S2A) but
increased during the chronic phase (d26 after immunization;
Ctrl. vs. acute: twofold, p > 0.05; Additional file 2: Figure
S2A). Pilot data indicates reduced abcg2-expression during
the acute phase in microvessels isolated from the spinal cord
(Ctrl. vs. acute: threefold, p < 0.05, n = 4–5, MWU test) but
not in brain microvessels (p > 0.05, n = 2–4, MWU test). In
peripheral organs, abcg2-expression was significantly
decreased in splenic T cells in the acute phase (fivefold,
p < 0.05; Additional file 2: Figure S2C) but not during
the chronic phase. abcg2-mRNA expression was also
reduced in the liver during the chronic phase (twofold,
p < 0.05; Additional file 2: Figure S2B).
We next investigated whether abcg2 has a functional
impact on the therapeutic effects of teri. Teri (10 mg/kg
body weight) administered therapeutically after individ-
ual disease onset of each animal (score > 1) was not
efficacious in wt animals as compared to respective
sham-treated controls (mean cumulative EAE score ±
SEM; wt teri 5.1 ± 0.3; wt vehicle 4.9 ± 0.3; Fig. 2a). In
contrast, using this teri dose, EAE disease course of
abcg2-KO mice was strongly ameliorated (abcg2-KO teri
3.9 ± 0.2; abcg2-KO vehicle 4.6 ± 0.3; Fig. 2a). Teri con-
centration within the spinal cord was significantly in-
creased in abcg2-KO mice after treatment (abcg2-KO
teri vs. wt teri, p < 0.05; Fig. 2b). Pilot data further indi-
cate higher teri concentration at similar CD3+ T cell
numbers in abcg2-KO mice in comparison to respective
wt animals (0–199 CD3+ cells/mm2: abcg2-KO = 277 ±
186.3 ng/mL, wt = 7.5 ± 7.5 ng/mL; 200–599 CD3+ cells/
mm2: abcg2-KO = 2207 ± 1211 ng/mL, wt = 727.5 ±
336.8 ng/mL; mean ± SEM; n = 2-3; p > 0.05, MWU
test). In contrast, teri concentrations in the plasma
(abcg2-KO teri 71656 ± 8553 ng/ml; wt teri 68472 ±
8300 ng/ml; mean ± SEM, n = 7–10, p > 0.05, Fig. 2c),
spleen (abcg2-KO teri 3155 ± 473 ng/g; wt teri 5514 ±
1077 ng/g; mean ± SEM; n = 7–8, p > 0.05, MWU test),
liver (abcg2-KO teri 35008 ± 3428 ng/g; wt teri 37,857 ±
3010 ng/g; mean ± SEM; n = 6–7, p > 0.05, MWU test),
and brain (abcg2-KO teri 453 ± 95 ng/g; wt teri 495 ±
123 ng/g; mean ± SEM; n = 9–10, p > 0.05, MWU test)
Fig. 1 Impact of abcg2-modulation on teri-induced effects in vitro. MACS sorted, activated splenic murine CD3+ T cells (α-CD3, 1 μg/mL; α-CD28, 10
ng/mL) from abcg2-KO and wt mice were treated with teri (12.5–100 μM) with or without ABCG2 inhibitor (FTC, 10 μM; Ko143, 10 μM). a Intracellular
teri concentration after 2-6 h incubation; HPLC; LC-MS/MS; n = 4, MWU-test: *p < 0.05. b Proliferation index after 48 h incubation; CSFE, flow cytometry;
n = 6-8, MWU-test: *p < 0.05; **p < 0.01; ***p < 0.001. c Apoptosis after 48 h incubation; Anx + PI, flow cytometry; n = 3, Wilcoxon test: *p < 0.05. wt:
C57BL/6 J wild-type mice; abcg2-KO: abcg2-deficient mice on C57BL/6 J background. teri, teriflunomide; FTC, Fumitremorgin C
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did not show significant differences between abcg2-KO
mice and wt animals. In non-immunized control animals
treated with 10mg/kg teri for 20 consecutive days, teri
concentrations in the spinal cord and plasma were similar
(spinal cord, abcg2-KO teri = 442 ± 160 ng/g; wt teri =
621 ± 280 ng/g; mean ± SEM, n = 3, p > 0.999, MWU test
and plasma, abcg2-KO teri = 63,949 ± 16,544 ng/mL; wt
teri = 82,766 ± 7553 ng/mL; mean ± SEM; n = 3, p >
0.999, MWU test). Lower teri dosages (5mg/kg and 7.5
mg/kg) did not show beneficial effects on EAE disease
course in wt or in abcg2-KO mice (data not shown).
Treatment effects of teri on EAE disease course were
corroborated histologically by 2.4-fold reduced demye-
lination of spinal cord tissue in teri-treated abcg2-KO
mice (p < 0.05) whereas teri-treated wt animals did not
exhibit a significant difference in comparison to respect-
ive sham-treated controls (Fig. 2d, e). During the chronic
disease phase, the inflammatory score or number of in-
filtrating CD3+ T cells, Mac3+ macrophages, and B220+
B cells in the spinal cord did not show statistically
significant differences of teri-treated mice compared to
vehicle-treated mice within both genotypes; however,
Fig. 2 Impact of abcg2-modulation on teri-induced effects in vivo. a Teri-treatment (10 mg/kg) of active MOG35–55 EAE, once daily p.o.,
individually after disease onset (score > 1). Data are pooled from three independent experiments with comparable results, each including both
genotypes and treatment groups, with a total of 48 mice (9–11 weeks old), number of animals in each group is indicated in the graph. Clinical
disease course was assessed using a 10-grade scale; Kruskal-Wallis test. Teri concentration within b the spinal cord and c plasma after treatment
of EAE (10 mg/kg body weight, 17–20 days) during active MOG35–55 EAE; HPLC; LS-MS/MS; n = 6–10; MWU test. d Percentage of demyelination
after MOG35–55 EAE; luxol fast blue staining (LFB) of spinal cord tissue; n = 7–10; MWU test. e Representative pictures of LFB staining (× 5
magnification, scale bar 200 μm; × 20 magnification, scale bar 50 μm). The percentage of demyelinated area was calculated as described in the
methods. Quantitative results were obtained at two sections of lumbar spinal cord per each mouse. wt: C57BL/6 J wild-type mice; abcg2-KO:
abcg2-deficient mice on C57BL/6 J background. teri, teriflunomide; statistics: *p < 0.05; **p < 0.01; ***p < 0.001
Thiele née Schrewe et al. Journal of Neuroinflammation            (2020) 17:9 Page 5 of 9
observations tended to be consistent with the clinical
scores (Additional file 3: Figure S3A–E).
At the peak of EAE (day 4 ± 1 after individual disease
onset), peripheral T cell subsets (CD4+CD45+ T cells,
CD8+CD45+ T cells, and CD4+CD25+FoxP3+ T cells;
spleen and inguinal lymph nodes) and cytokine produc-
tion of T cells (IFN-γ, IL-17, GM-CSF, IL-4, and IL-10)
were similar in abcg2-KO and wt mice treated with 10
mg/kg teri or vehicle (Additional file 4: Figure S4).
Discussion
Here, we identify ABCG2 as a determinant of teri-
induced effects in a murine model of MS. Increased
intracellular teri concentration in T cells lacking abcg2
indicates that teri is a substrate for active cellular drug
efflux in this model. Functional relevance of abcg2-defi-
ciency and pharmacological inhibition was shown by
increased teri-induced cellular effects on proliferation
and apoptosis. In EAE, abcg2-mRNA is differentially
expressed during the acute and chronic disease stages
and in different potential target tissues and cells, and
abcg2-deficiency leads to increased therapeutic effects
accompanied by an increased teri concentration within
the spinal cord.
Teri concentrations used in our in vitro experiments
were matched to steady-state plasma concentrations of
20–60mg/L (equivalent to approximately 100–300 μM)
reached in humans treated with the approved dose of 7
or 14 mg/day [21]. Intracellular teri concentration was
more than twofold higher in abcg2-deficient T cells after
short incubation time of 2–6 h. Pharmacological inhib-
ition of abcg2 led to an increase of teri-induced apop-
tosis in murine T cells at the highest teri concentration
(100 μM). Using the same concentration, no cytotoxic
effects were detected in human lymphocytes, which is in
line with previous data [18].
Rodent and human ABCG2 is expressed in most CNS
cells with highest expression at physiological barriers like
the BBB or blood-spinal-cord barrier [5, 22, 23]. Due to
its function at physiological barriers, abcg2 influences
the pharmacokinetics of pharmaceutical drugs [1]. This
is also likely for teri for which a significant amount was
found to be excreted into milk (> 23%) in lactating rats
[24] which corresponds to well-known functions of
abcg2 contributing to the accumulation of drugs in milk
shown in mice [25]. However, although the summary of
product characteristics states that teri is a substrate of
ABCG2 [7], detailed human data are lacking. Our data
indicate that intracellular and tissue levels rather than
mere plasma levels are likely to be of relevance. En-
dogenous substrates of ABC transporters include
chemokines and cytokines, suggesting a potential contri-
bution to neuroinflammation and degeneration. Alter-
ations of ABC-transporter activity were demonstrated in
active MS-lesions [26]. In addition to inflammatory and
oxidative stress [22], apolipoprotein E was also shown to
regulate transporter abundancy and localization at the
BBB in an experimental stroke model [20]. In peripheral
organs, reduced abcg2-expression during the chronic
phase of EAE was observed in splenic T cells. Also, liver
abcg2-expression was reduced during EAE, whereas teri
plasma levels were not different between genotypes. Our
data also indicates that abcg2-deficiency alone does not
change systemic CNS steady-state teri concentrations
which are reached after repeated teri doses in mice after
approximately 1 month [24]. Hypothetically, abcg2-ex-
pression by microvessels and infiltrating (T) cells
regulated during EAE may have an impact on teri con-
centration within the autoimmune inflamed spinal cord.
Taken together with our in vitro results, we also
hypothesize on abcg2-dependent effects on teri efficacy
occurring during peripheral T cell proliferation. How-
ever, to elucidate the exact site(s) of action of teri and
additional impact of abcg2, further experiments includ-
ing conditional and chimeric animal models are needed
as well as experiments on potential functional redun-
dancy. Furthermore, abcg2-dependent effects on pleio-
tropic mechanisms of action of teri (i.e., T cell
mitochondrial respiration [11];) with emphasis on teri
concentrations within cell organelles would be interest-
ing to investigate. However, these aspects were beyond
the scope of the current study which set out to investi-
gate if abcg2 has an effect on teri-treatment in vivo.
Our findings support a functional relevance of abcg2
in vivo, since a suboptimal teri dosage without clinical
effect in wt animals strongly ameliorated the EAE dis-
ease course in abcg2-KO mice, corroborated by reduced
spinal cord demyelination. In addition to mere tissue teri
concentrations altered drug kinetics may be relevant.
However, whether plasma concentrations in abcg2-KO
mice increase more rapidly than in wt mice remains to
be determined and also tissue concentrations may
behave differently. Teri shows strain- and species-
dependent differences with higher dosages required for
effects on EAE disease onset and/or severity in mice (10
mg/kg/day) than in rats (3–10mg/kg/day) [13, 14]. In
the MOG-induced C57BL/6 EAE model, 10 mg/kg teri
administered prophylactically (i.e., before onset of signs)
prevents disease occurrence [14]. In MOG35–55 EAE in
C57BL/6 J wt mice, teri has no effect in a therapeutic
setting (i.e., after onset of signs) at tolerable concentra-
tions (teriflunomide Investigator Brochure 2019, internal
Sanofi data). In order to address our hypothesis of in-
creased teri effects in abcg2-deficient mice, the well-
tolerated teri dose which is prophylactically efficacious
in MOG-EAE (10 mg/kg, starting on day 3 after
immunization [14];) was used in our setting with a
therapeutic teri administration after onset of signs.
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Finally, the dosage used in our experiments is compar-
able to the human situation with steady-state plasma
concentrations in wt mice (68 ± 83 μg/mL) comparable
to the steady-state plasma concentrations in humans
undergoing therapy with teri with the approved dosages
of 7 or 14 mg (20–60 μg/mL) [21].
Different studies suggest that teri has a significant in-
fluence on the inflammatory response of various im-
mune cells including reduction of proinflammatory
cytokines and modulation of innate immune functions
associated with decreased neurotoxicity (e.g., [27, 28]).
Our data indicates that in the animal model, therapeutic
modulation of teri efficacy in abcg2-KO mice is not as-
sociated with a modulation of peripheral T cell popula-
tions. In MS patients treated with teri and in rodents
suffering from EAE treated with the respective prodrug
leflunomide, it was demonstrated that different T cell
populations were selectively affected with a preferential
reduction in Th1 effector cells [11]. The differences ob-
served may be explained by different drugs, treatment
duration, or therapeutic setting.
Single nucleotide polymorphisms (SNP) in the
ABCG2 gene can alter protein expression and activity
[1]. Both ABCB1 and ABCG2 genes are highly poly-
morphic with a high frequency of functionally rele-
vant variant alleles in different MS populations [5].
Functional relevance for MS treatment was demon-
strated with the well-characterized ABCG2 substrate
mitoxantrone. In retrospective analyses, association of
SNPs in ABCB1 and ABCG2 genes with drug effects
has been shown at least for relapsing and secondary
progressive MS [5] but not for primary progressive
MS [29]. During treatment with leflunomide, oral
clearance of its active metabolite teri was associated
with ABCG2 SNPs [21].
Conclusion
Since ABC transporters are highly conserved between
rodents and humans [30], our study which demon-
strates an impact of abcg2 on teri-treatment in the
animal model of MS argues for further investigations
on functional relevance of abcg2-modulation on spe-
cific substrates such as teri. Thus far, pharmaco-
logical inhibition of respective ABC-transporters as a
therapeutic approach has been unsuccessful despite
several efforts especially in oncology [2]. Therefore,
further investigation of pharmacogenomic association
of ABCG2, spatiotemporal regulation under the influ-
ence of different drugs, potential redundancy, and
functional consequences are needed to substantiate
the biologically plausible claim that ABC transporters
and their modulation may impact individual treat-
ment responses.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12974-019-1677-z.
Additional file 1: Figure S1. Cytokine expression of splenic CD4+CD45+
and CD8+CD45+ T cells after in vitro stimulation with teri. Splenocytes
from abcg2-KO and wt mice were treated with teri (100 μM; 2 h) and
assessed for cytokine expression by flow cytometry. (A) Gating strategy to
identify CD4+CD45+ and CD8+CD45+ T cells. (B) Percentage fraction of
CD4+CD45+ and CD8+CD45+ cells. Cytokine expression of CD4+ T cells (C)
and of CD8+ T cells (D). Cells isolated from n=6 mice per genotype were
divided in 2 treatment groups (DMSO and 100 μM teri). Two-Way ANOVA
(Turkey’s multiple comparison test): *p<0.05; **p<0.01; ***p<0.001. wt:
C57BL/6J wild type mice; abcg2-KO: abcg2-deficient mice on C57BL/6J
background; teri: teriflunomide.
Additional file 2: Figure S2. Differential abcg2-expression during
experimental autoimmune encephalomyelitis. Relative abcg2-mRNA
(quantification by TaqMan PCR using ΔΔct method; normalized to ß-
actin) during the acute or chronic phase of MOG35-55 EAE in female
C57BL/6 J wild type mice compared to healthy controls. (A) spinal cord,
Kruskal-Wallis test; (B) liver, MWU-test; (C) splenic T cells, Kruskal-Wallis
test; (D) spleen, MWU-test. Ctrl: healthy control; ac EAE: acute phase of
EAE (d16/18 after immunization); chr EAE: chronic phase of EAE (d26 after
immunization); statistics: *p<0.05; **p<0.01.
Additional file 3: Figure S3. Histolopathological characterization of
spinal cords of abcg2-KO and wt mice after teri-treatment (10 mg/kg
body weight, 17-20 days) during active MOG35-55 EAE. (A) Inflammatory
score of spinal cord lesions (H&E staining); evaluated as inflammatory
score as described in the methods, obtained at two sections of spinal
cord tissue per each mouse. (B) Representative pictures of H&E staining
(40x magnification, scale bar 20 μm). Quantification of (C) CD3+ cells
(T-cells), (D) Mac3+ cells (macrophages) and (E) B220+ cells (B-cells);
evaluated as cells/mm2, obtained at two sections of spinal cord tissue per
each mouse. A-D: n=6-13; MWU-test, p=ns. wt: C57BL/6J wild type mice;
abcg2-KO: abcg2-deficient mice on C57BL/6J background; teri:
teriflunomide.
Additional file 4: Figure S4. Immunomodulation of T cell responses
after teri-treatment during MOG35-55 EAE: Cytokine expression
CD4+CD45+ and CD8+CD45+ T cells from spleen (A-D) and inguinal
lymphnodes (E-H) and percentage of CD25+FoxP3+ of CD4+ T cells from
spleen and inguinal lymphnodes (I-J). Teri-treatment (10 mg/kg) of active
MOG35-55 EAE, once daily p.o. (4±1 days), individually after disease onset
(Score>1) in abcg2-KO and wt mice. (A, E) Gating strategy to identify
CD4+CD45+ and CD8+CD45+ T cells. (B, F) Percentage fraction of
CD4+CD45+ and CD8+CD45+ cells. Cytokine expression of CD4+ T cells (C,
G) and of CD8+ T cells (D, H). (I) Gating strategy to identify CD25+FoxP3+
cells of CD4+ cells. (J) Percentage portion of CD4+CD25+FoxP3+ cells. Data
were assessed by flow cytometry. Two-Way ANOVA (Turkey’s multiple
comparison test): *p<0.05; **p<0.01. wt: C57BL/6 J wild type mice; abcg2-KO:
abcg2-deficient mice on C57BL/6 J background; teri: teriflunomide; LN:
inguinal lymphnodes.
Additional file 5: Figure S5. Gating strategies of proliferation and
apoptosis assays (see Fig. 1). (A) Gating strategy to identify the fraction of
proliferating CFSE+PI- T cells. Representative figures of wt T cells treated with
DMSO or teri (100 μM teri) for 48 h. Proliferation index was calculated as
follows: normalized to ∅ cell death ( ¼ %Proliferation ð100−∅cell deathÞ100 );
quotient vehicle-treated cells to teri-treated cells (¼ %proliferation ðvehicleÞ%proliferation ðteriÞ x (-1)).
(B) Gating strategy of apoptosis to identify percentage fraction of apoptotic
T cells. Representative picutres of wt cells treated with DMSO for 48 h.
Apoptosis was calculated as sum of Anx+, AnxPI+ and PI+ T cells.
Additional file 6: Table S1. Flow cytometry antibodies.
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Thiele née Schrewe et al. Journal of Neuroinflammation            (2020) 17:9 Page 7 of 9
macrophage colony-stimulating factor; H&E: Hematoxylin and eosin;
HPLC: High-performance liquid chromatography; IFN-γ: Interferon gamma;
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